intracranial aneurysms, one question has emerged: does the inability of endovascular therapy to remove subarachnoid blood prior to cisternal clot lysis result in a higher CSF concentration of potential spasmogens, with the potential for more severe vasospasm? 16 Big ET-1 is the active precursor substance of mature 21-residue ET-1 and probably provides the best information about the activation of the ET system of patients in the acute phase after SAH. 4, 18, 24 The purpose of the present study was therefore to measure serially serum and CSF concentrations of big ET-1 in a population of patients with SAH receiving on of the following treatments: 1) early (within 72 hours of SAH) aneurysm surgery, 2) early endovascular treatment, or 3) no intervention in the acute phase. Patients undergoing neurosurgical operations were exposed to the highest physiological stress-craniotomy and microdissection of the cerebral vasculature-but potentially benefited from the intraoperative removal of a cisternal clot. 10, 19, 22 In patients receiving endovascular treatment there was no disturbance of the cerebral vasculature other than intraluminal microcatheterization, but they also did not undergo cisternal clot removal. In patients receiving only medical treatment in the acute phase no surgery trauma other than ventriculostomy was induced.
CLINICAL MATERIAL AND METHODS

Patient Population
The present study is based on a consecutive series of 44 patients who met the following criteria: 1) SAH confirmed by CT scanning of the head; 2) intracranial aneurysm(s) demonstrated on cerebral angiography; 3) admission within 3 days of the initial SAH; and 4) ventriculostomy for treatment of acute posthemorrhagic hydrocephalus. Intraventricular catheters were placed either at admission or at the time of aneurysm surgery. Only those patients requiring ventriculostomies for the treatment of posthemorrhagic hydrocephalus were included; that is, no intraventricular catheters were placed for study purposes only. The study protocol was approved by the Institutional Review Board of the University of Vienna Medical School.
Patient demographics are given in Table 1 . Patients ranged in age from 24 to 80 years (51.3 Ϯ 14.2 years [mean Ϯ SD]). The male/female ratio was 1:1.4. Fifteen patients or 34.1% of the study population underwent early microsurgical treatment in which a clip was placed on the ruptured aneurysm. Seventeen patients (38.6%) with ruptured aneurysms received early endovascular treatment in which we used electrolytically detachable platinum coils (Guglielmi Detachable Coil) system; Target Therapeutics/ Boston Scientific, Fremont, CA). 17 Twelve patients (27.3%) who were admitted in the acute phase after aneurysmal SAH were not treated within the first 2 weeks of onset; these patients were either of advanced age, presenting with internal comorbidities, or were in poor neurological condition, harboring aneurysms not amenable to palliative embolization. Additionally, four patients in whom ventriculoatrial shunts were placed to treat nonhemorrhagic hydrocephalus served as a non-SAH control group but were not considered part of the study population.
The following data were analyzed in a prospective fashion. 1) The severity of neurological impairment on admission was determined by obtaining the Hunt and Hess grade; 21 in patients who were sedated and mechanically ventilated on admission, the neurological condition prior to sedation and injection of neuromuscular blockade was recorded.
2) The volume of subarachnoid, intracerebral, and intraventricular blood was measured on CT scans obtained at admission, stratified as Fisher CT grades; 11 Fisher CT Grades 1 and 2 were pooled for the purpose of analysis. 3) Maximum mean cerebral blood flow velocity was measured in the main trunk of the middle cerebral artery and %⌬CBFV. 4) Serum and CSF concentrations of big ET-1 were measured during the first 2 weeks after SAH. 5) The incidence of delayed ischemic infarction was determined on follow-up CT scans. 6) Six-month clinical outcome was assessed according to the GOS score. 23 Transcranial Doppler ultrasound monitoring was performed daily with a 2-MHz range gated pulsed Doppler ultrasonography unit (Multidop L, DWL, Germany). The main trunk of the MCA was insonated, and the segment with the highest mean CBFV value was recorded. The CBFV max 1,2 and %⌬CBFV 14, 16 values were used for analysis. In patients with severe vasospasm, as estimated from TCD recordings (CBFV max > 200 cm/second), angiography was repeated.
The most recent CT scan obtained in every patient was reviewed. Hypodense areas visualized on CT scans were classified as related to initial intracerebral hemorrhage, related to treatment, or related to vasospasm. A vasospasmrelated infarction was defined as delayed in onset: 1) not present on the postintervention CT scan obtained within 48 hours of treatment or 2) not present on the corresponding follow-up CT scan obtained in the untreated patients. Paired blood and CSF samples (2 ml) were drawn during the first 2 weeks after SAH. Sample 1 was drawn between Days 0 to 2 (median 1) post-SAH. Samples 2, 3, 4, and 5 were drawn between Days 3 to 5 (median 3), Days 6 to 8 (median 6), Days 9 to 11 (median 9), and Days 12 to14 (median 12) post-SAH, respectively. Blood and CSF samples were centrifuged at 3000 rpm for 5 minutes and stored at Ϫ80°C until they were assayed. Determination of big ET-1 was performed using a sandwich enzyme-linked immunosorbent assay (Biomedica GmbH, Divischgasse 4, Vienna, Austria). Ten different samples of serum and CSF were assayed directly in the test without spike and spiked with 0.5 fmol/l and 2.0 fmol/l of human big ET-1 (American Peptide Company, Sunnyvale, CA) to validate the results; recovery was 92% (range 85-104%) in serum and 107% (range 97-116%) in CSF.
All data are presented as the mean Ϯ standard deviation. Comparisons between chi-square test for contingency tables (SPSS/PC+, V 4.0 and StatView, V4.5). Statistical analysis of sequential data over time was performed using an analysis of variance. A p value of Ͻ 0.05 was considered statistically significant.
RESULTS
Big ET-1 was detected in both CSF and serum throughout the study period. The mean levels of big ET-1 in the CSF of patients with SAH were significantly higher than those in the non-SAH control group (1.91 Ϯ 0.64 pg/ml and 1.01 Ϯ 0.55 pg/ml, respectively; p = 0.02). The CSF concentrations of big ET-1 were positively correlated with delayed ischemic infarction (p = 0.01; Table 2 ) as well as the treatment modality applied (p = 0.01; Table 3 ). No such correlations could be established for the post-SAH big ET-1 serum levels.
Higher big ET-1 CSF concentrations were found in patients suffering delayed ischemic infarctions than in those without infarctions (2.14 Ϯ 0.79 pg/ml and no 1.83 Ϯ 0.57 pg/ml, respectively; p = 0.01, Table 2 ). This was true for patients undergoing acute open surgery (with infarction, 1.84 Ϯ0.83 pg/ml and without infarction 1.73 Ϯ 0.52 pg/ml), early endovascular treatment (with infarction 2.19 Ϯ 0.54 pg/ml and without infarction 2.01 Ϯ 0.48 pg/ml), and no intervention in the acute phase (with infarction 2.48 Ϯ 1.03 pg/ml and without infarction 1.74 Ϯ 0.68 pg/ml). Levels of big ET-1 CSF in patients with and without delayed ischemic infarctions did not differ at admission (1.97 Ϯ 0.64 pg/ml 2.06 Ϯ 0.61 pg/ml, respectively), but higher levels were detected thereafter in those suffering delayed strokes (Days 3-5: 2.94 Ϯ 0.76 pg/ml and 1.83±0.81 pg/ml [not significant]; Days 6-8: 2.04 Ϯ 0.85 pg/ml and 1.74 Ϯ 0.46 pg/ml [not significant] in those with and without infarction, respectively; Fig. 1 In patients who underwent acute-phase aneurysm surgery lower big ET-1 CSF concentrations were found than in those receiving embolization or no treatment-the nonsurgical treatment groups (microsurgical treatment group 1.76 Ϯ 0.61 pg/ml and nonsurgical groups 1.99 Ϯ 0.65 pg/ml; p = 0.02; Table 3 ). This was true for patients with (microsurgical treatment 1.84 Ϯ 0.83 pg/ml and nonsurgical treatment 2.28 Ϯ 0.73 pg/ml) and without delayed infarctions (microsurgical treatment 1.73 Ϯ 0.52 pg/ml and nonsurgical treatment, 1.89 Ϯ 0.58 pg/ml) (Fig. 2 upper) . When the subgroup of untreated patients was excluded from this analysis, patients undergoing early aneurysm surgery were still shown to have lower big ET-1 CSF concentrations than those receiving early endovascular treatment (microsurgical treatment 1.76 Ϯ 0.61 pg/ml and embolization, 2.06 Ϯ 0.51pg/ml, p = 0.01). This was true for patients with (microsurgical treatment, 1.84 Ϯ 0.83 pg/ml and embolization 2.19 Ϯ 0.54 pg/ml) and without delayed infarctions (microsurgical treatment 1.76 Ϯ 0.61 pg/ml and embolization 2.01 Ϯ 0.48 pg/ml) ( Fig. 2  lower) , although statistical significance was only reached among patients in whom delayed infarctions did not occur. Neurological outcomes and delayed stroke rates were similar for the microsurgical and the endovascular treatment groups (p = 0.15, Table 2 ), whereas untreated survivors of aneurysmal SAH fared significantly worse (p = 0.02, Table 2 ).
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Post-SAH serum and CSF endothelin concentrations 3 27, 28, 37 thrombin, 30 and transforming growth factor ␤-1. 33 In the "endothelin hypothesis" it is suggested that an abluminal clot stimulates vascular endothelium to produce ETs and that ET-1 and its intermediate precursor, big ET-1, are among the factors inducing the prolonged vasoconstriction of vasospasm. 27, 28, 31, 37, 48, 50 Studies in which elevated post-SAH serum and CSF ET concentrations are reported are usually performed in patients undergoing neurosurgical operations, such as craniotomy and clipping of the ruptured aneurysm. 12, 36, 42, 44 The influence of such major surgical interventions on ET levels is unknown. On one hand, it has been suggested that increased ET concentrations observed in the perioperative period could be the consequence of surgically induced disturbances of the cerebral parenchyma and/or vasculature; 7, 16, 18 recently published studies reporting elevated cytokine levels following neurosurgical interventions may add support to this notion. 39, 46 On the other hand, the amount of subarachnoid blood found in the basal cisterns is highly predictive of the risk for delayed ischemia and infarction. 11, 29 Whereas removal of subarachnoid blood is possible during early-stage aneurysm surgery, this obviously cannot be performed in aneurysms treated by endovascular techniques. One could therefore argue that the levels of potential spasmogens in the CSF in patients receiving endovascular treatment might be higher, with the potential for more severe vasospasm. 10, 16, 19, 22 Because big ET-1 concentrations were tested for correlation with delayed ischemic stroke and the treatment modality applied, certain possible limitations of the present study deserve consideration. First, although several lines of evidence link increased post-SAH ET concentrations to vasospasm, 6, 12, 32, 34, 36, 42, 44, 47, 49, 50 it remains unclear whether ETs are causative factors mediating vasospasm or, conversely, are the result of an ischemic glial ET production. Indeed, the authors of recent studies have questioned the role of ET overexpression in the pathogenesis of vasospasm. Experiments in primate models have failed to demonstrate a significant elevation of ET-1 in CSF after SAH, demonstrating, instead, increases in cerebral ET-receptor expression. 20 This observation argues for complex changes in the ET system rather than isolated ET overproduction following SAH. In other studies the authors have demonstrated increased ET-1 concentrations in serum, CSF, and brain parenchyma following both focal and global ischemia in a rat model. 5 Increased levels of ET-1 were also found after nonhemorrhagic stroke in humans. 51 The authors of recent studies argue that ET overexpression after SAH is more likely caused by hypoxia/ischemia-induced ET production in astrocytes than as a result of oxyhemoglobin-induced ET release in endothelial and vascular smooth muscle cells. 40 Alternatively, because the human ET-1 gene contains a consensus sequence for acute-phase elements, ET production could be associated with the stress-induced release of acute-phase proteins following SAH. 13 Other investigators have suggested that impairment of the blood-brain barrier after SAH might facilitate leakage of plasma ETs into the CSF space. 28, 37 These findings, however, do not invalidate the results of our study, because elevated ET concentrations apparently parallel the course and severity of cerebral ischemia. 5, 40, 42, 51 Second, because only patients requiring ventriculostomy for treatment of acute posthemorrhagic hydrocephalus were included in this study, a population of patients with poor-grade aneurysm was preselected. This becomes evident when the study population is compared with those 36 SAH patients who were also treated acutely during the study period but who were excluded because they did not undergo ventriculostomy. In detail, these patients presented with lower Hunt and Hess grades (mean 2.31 Ϯ 1.26 [range I-V, median 2]) as compared with study population (mean 3.43 Ϯ 0.95 [range I-V, median 4]), had a lower delayed ischemic stroke rate (19.4% as compared with study population 38.6%), and had a better neurological A. Gruber, et al. Third, patients were nonrandomly distributed between the treatment groups. The treatment choice was made by a team of neurosurgeons experienced in both microsurgery and endovascular treatment and was based on evolving experience and clinical criteria developed at this center. 41 The authors strongly argue that, however desirable for study purposes, randomization between open surgery and endovascular treatment is possible in only a small proportion of patients treated acutely after aneurysmal SAH. Despite this limitation, the treatment groups were matched for presenting Hunt and Hess grades and admission Fisher CT grades. There was a trend toward a higher Hunt and Hess grade in the endovascular and untreated groups, which, however, failed to reach statistical significance (Table 1) . Patients receiving early endovascular treatment were younger than those undergoing open surgery or no intervention (p = 0.02, Table 1 ). In agreement with previous studies, we observed a positive correlation between patient age and CSF ET concentrations, 42 although statistical significance was not reached. Moreover, the treatment groups were not matched for aneurysm locations (p = 0.004, Table 1 ), because posterior circulation aneurysms were not surgically treated in the acute phase. Fourth, CBFV max and %⌬CBFV as measured by TCD ultrasonography were used to estimate the severity of delayed-onset vasospasm. In light of the finite risk of angiography 8 and the correlation of noninvasive TCD data with vasospasm, 15, 35 we conducted repeated angiography only in patients with severe vasospasm that was diagnosed by the occurrence of delayed ischemic neurological deficits and/or estimated from TCD recordings (CBFV max > 200 cm/second). For the purposes of this study, we considered CBFV max , %␦CBFV, and the occurrence of delayed infarctions on CT scanning sufficient descriptors of vasospasm, because in the clinical setting the presumptive diagnosis of vasospasm was made on the basis of delayed ischemic neurological deficits and/or TCD values, and, additionally, because delayed infarctions revealed on CT scanning were considered confirmation of the presumptive diagnosis.
Notwithstanding these aforementioned limitations, the results of this study showed that the levels of big ET-1 in the serum and ventricular CSF of patients with SAH were significantly higher than those determined in non-SAH control group. Big ET-1 CSF concentrations were positively correlated with the occurrence of delayed ischemic stroke and the treatment modality applied, whereas no such correlations could be established for big ET-1 serum levels.
The demonstrated positive correlation between elevated big ET-1 CSF concentrations and delayed ischemic stroke is in agreement with previous studies in which the authors reported elevated ET levels in the setting of cerebral ischemia. 5, 41, 50 Our findings thereby concur with those of previous studies in which higher ET concentrations 42, 45 and increased CBFV max 1,2,43 and %⌬CBFV 14 were demonstrated in patients suffering SAH with delayed-onset vasospasm; however, our findings fail to establish a clearcut correlation between TCD values and ET levels.
Because big ET-1 CSF concentrations were lowest in the microsurgery-treated subgroup, the results of the present study do not support the contention that elevated post-SAH ET levels are the consequence of a surgically induced disturbance of the cerebral parenchyma and/or vasculature. In contrast, big ET-1 CSF levels were lowest in surgically treated patients without delayed infarctions, whereas the highest concentrations were found in untreated patients with delayed infarctions. When the relationship between big ET-1 CSF levels and delayed infarction was tested after exclusion of the untreated subgroup, (that is, those patients receiving a less aggressive hypervolemic hypertensive treatment to avoid aneurysm rerupture), big ET-1 CSF concentrations were still found to be lower in the microsurgery-treated subgroup. Hence, we found that among SAH patients matched for presenting Hunt and Hess grades and Fisher CT grades, treated by the same team of physicians at the same institution, and treated with the same pre-, peri-, and postoperative intensive care treatment protocol, that those undergoing early aneurysm surgery with attempted intraoperative cisternal clot removal were shown to have lower big ET-1 CSF levels than those receiving early endovascular treatment. The clinical sig-
Post-SAH serum and CSF endothelin concentrations nificance of the lower big ET-1 CSF concentration in the microsurgery-treated subgroup, however, must be interpreted with caution. First, this difference reached statistical significance only in patients in whom delayed infarctions did not occur. In the clinically relevant subgroup, (patients suffering delayed strokes) big ET-1 CSF concentrations did not differ significantly between the microsurgery and the endovascular treatment groups. Second, the microsurgery and the endovascular treatment groups did not differ significantly in: 1) the severity of vasospasm as measured by CBFV max and %⌬CBFV, 2) incidence of delayed infarctions, and 3) neurologic outcome based GOS score. There was an insignificant trend toward a higher delayed stroke rate in the endovascular treatment group, which paralleled the trend toward a higher admission Hunt and Hess grade in this subpopulation. Third, even if the inability to remove subarachnoid blood timely, (that is, prior to cisternal clot lysis and liberation of potential spasmogens), in the endovascular-treated group was a factor that substantially contributed to the higher big ET-1 CSF levels in the endovascular subgroup, it still remained unclear why patients receiving acute-phase embolization treatment without infarctions had higher big ET-1 CSF levels than patients undergoing acute-phase microsurgery with delayed infarctions (embolization/no infarction 2.01 Ϯ 0.48 pg/ml; microsurgery with infarction 1.84 Ϯ 0.83 pg/ml). Because vasospasm is multifactorial in origin and the definite role of ETs remains to be established, a possible explanation is that surgery resulted in reduced levels of big ET-1 but not reduced levels of other potential spasmogens in the CSF space. Clinical outcomes and delayed stroke rates may therefore not have been improved by early-stage aneurysm surgery, but lower big ET-1 CSF concentrations could have been produced.
Although the small study population imposed limitations on our abilities to draw clinically robust conclusions in relation to a possible difference in the severity of vasospasm among the treatment groups, we found that neurological outcomes and delayed stroke rates were similar for the microsurgery-and the endovascular-treated groups; a possible clinical significance of higher big ET-1 CSF levels observed in patients who received acute-phase embolization therefore remains to be established in future clinical trials. Notwithstanding the small study population, this finding is in agreement with previous observations indicating that the severity of delayed-onset vasospasm in patients undergoing early endovascular treatment of ruptured aneurysms may not differ significantly from that in patients who undergo early aneurysm surgery. 16, 38 This assumption does not negate the importance of subarachnoid blood for the development of vasospasm and delayed ischemic infarction 11, 29 but rather indicates that our attempts to remove physically cisternal clots during earlystage aneurysm surgery might have been insufficient. 3, 25, 26 In turn, should intraoperative pharmacological 9 clot removal prove successful in preventing delayed-onset vasospasm, future studies regarding the influences of the chosen treatment modality on vasospasm and delayed infarction should include a subgroup treated with this technique so that the results of early aneurysm surgery with pharmacological intraoperative clot removal can be compared with those obtained in early endovascular treatment.
